Gene To GMP, Translating Concept Into Cure

Advancing genetic medicine requires seamless integration across development stages, yet many programs still rely on fragmented supply chains and legacy materials. A new approach centers on unifying synthetic DNA production with advanced therapy development and GMP manufacturing within a single platform. By replacing plasmid-based systems with enzymatically produced, cell-free DNA, this model reduces contamination risks, shortens production timelines, and simplifies scalability. Integrated capabilities span multiple modalities, including viral vectors, cell therapies, and mRNA, allowing programs to move from early-stage development to clinical supply without vendor handoffs. Coordinated process development, analytics, and regulatory support further minimize knowledge gaps and accelerate progress toward IND readiness. With a focus on speed, flexibility, and end-to-end execution, this platform is designed to streamline the path from genetic design to clinical-grade therapies.